Mast Cell Inhibitors for Chronic Pelvic Pain Syndrome Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic pelvic pain syndrome (CPPS) lacks effective diagnostic criteria and treatment options, with patients often misdiagnosed with bacterial prostatitis and subjected to costly and ineffective antibiotic treatments due to the unclear etiology and similarity of symptoms.
Innovation Solution
The use of mast cell inhibitors, such as mast cell stabilizers and histamine receptor antagonists, along with inhibitors of MCP-1 and MIP-1α, to treat and prevent CPPS, combined with biomarkers like mast cell tryptase for diagnosis and monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic treatment is used for CPPS patients, then bacterial prostatitis may be treated, but unnecessary treatment costs and side effects increase due to misdiagnosis
Solution Approach 1:
The patent applies preliminary action by measuring mast cell tryptase levels before initiating antibiotic treatment to determine whether the patient actually has bacterial prostatitis or CPPS. This preliminary diagnostic step prevents unnecessary antibiotic prescriptions and associated costs while ensuring appropriate treatment for the actual condition.
2Object-affected harmful factors
If mast cell inhibitors are used to treat CPPS, then pelvic pain is reduced, but treatment complexity increases due to multiple inhibitor types
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of mast cell inhibitors to improve their selectivity and efficacy. By changing molecular parameters such as receptor binding affinity and tissue distribution, the treatment becomes more targeted and effective, reducing pain while maintaining manageable complexity through optimized drug properties rather than multiple agents.
Data Source
AI summary
The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1α) to treat or prevent chronic pelvic pain syndrome.